<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096343</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000377728</org_study_id>
    <secondary_id>UAB-0137</secondary_id>
    <nct_id>NCT00096343</nct_id>
  </id_info>
  <brief_title>Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer</brief_title>
  <official_title>A Phase II Trial of Pre-Operative Taxol and Carboplatin in Women With Newly Diagnosed Locally Advanced Operable Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different&#xD;
      ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy&#xD;
      before surgery may shrink the tumor so that it can be removed. Combining paclitaxel with&#xD;
      carboplatin may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving paclitaxel together with carboplatin&#xD;
      works in treating women who are undergoing surgery for newly diagnosed, locally advanced&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the clinical and pathological response in women with newly diagnosed, locally&#xD;
           advanced operable breast cancer treated with neoadjuvant chemotherapy comprising&#xD;
           paclitaxel and carboplatin.&#xD;
&#xD;
        -  Evaluate specific biomarkers for prognostic value and as markers for response/resistance&#xD;
           in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the tolerability and toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients with non-palpable lymph nodes undergo sentinel lymph node biopsy within 4 weeks&#xD;
      before beginning neoadjuvant chemotherapy.&#xD;
&#xD;
      All patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on&#xD;
      day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo lumpectomy or modified radical mastectomy. Patients with a positive sentinel&#xD;
      lymph node biopsy or palpable axillary adenopathy undergo axillary lymph node dissection. All&#xD;
      patients undergoing lumpectomy or mastectomy with high-risk disease also undergo&#xD;
      radiotherapy.&#xD;
&#xD;
      Patients refusing lumpectomy or mastectomy due to persistence of disease may undergo core&#xD;
      needle biopsy.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the clinical and pathological response in women with newly diagnosed, locally advanced operable breast cancer treated with neoadjuvant chemotherapy comprising paclitaxel and carboplatin</measure>
    <time_frame>baseline to 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate specific biomarkers for prognostic value and as markers for response/resistance in patients treated with this regimen</measure>
    <time_frame>baseline through 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the tolerability and toxicity of this regimen in these patients.</measure>
    <time_frame>baseline to 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel IV followed by Carboplatin IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>Paclitaxel IV followed by Carboplatin IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>Paclitaxel IV followed by Carboplatin IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive ductal carcinoma or invasive lobular carcinoma of&#xD;
             the breast meeting the following stage criteria:&#xD;
&#xD;
               -  T2, T3, or T4a-c&#xD;
&#xD;
               -  N0-2&#xD;
&#xD;
               -  M0&#xD;
&#xD;
          -  Inflammatory breast cancer (stage IIIB) allowed&#xD;
&#xD;
          -  Measurable disease by mammogram or ultrasound&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.2 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No comorbid medical condition that would preclude study participation&#xD;
&#xD;
          -  No comorbid infection that would preclude study participation&#xD;
&#xD;
          -  No clinically significant peripheral neuropathy (&gt; grade 1)&#xD;
&#xD;
          -  No prior significant allergic reaction to drugs containing Cremophor, such as&#xD;
             teniposide, cyclosporine, or vitamin K&#xD;
&#xD;
          -  No dementia or altered mental status that would prohibit understanding of informed&#xD;
             consent&#xD;
&#xD;
          -  No other primary malignancy except non-melanoma skin cancer or carcinoma in situ of&#xD;
             the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent prophylactic growth factors&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 3 weeks since prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent anticancer drugs&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisle M. Nabell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2004</study_first_posted>
  <last_update_submitted>November 30, 2018</last_update_submitted>
  <last_update_submitted_qc>November 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Lisle Nabell</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <keyword>invasive ductal breast carcinoma</keyword>
  <keyword>invasive lobular breast carcinoma</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>inflammatory breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

